IQVIA Holdings Inc. $IQV Stock Position Lowered by Aberdeen Group plc

Aberdeen Group plc trimmed its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 4.0% during the 3rd quarter, HoldingsChannel reports. The firm owned 137,993 shares of the medical research company’s stock after selling 5,810 shares during the quarter. Aberdeen Group plc’s holdings in IQVIA were worth $24,938,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Eubel Brady & Suttman Asset Management Inc. acquired a new position in shares of IQVIA during the 3rd quarter valued at about $14,278,000. OPTIMAS CAPITAL Ltd acquired a new position in IQVIA during the third quarter valued at approximately $4,008,000. Amundi grew its holdings in IQVIA by 46.3% during the second quarter. Amundi now owns 1,279,817 shares of the medical research company’s stock valued at $210,722,000 after purchasing an additional 405,250 shares during the last quarter. Diversified Trust Co lifted its stake in shares of IQVIA by 57.2% in the third quarter. Diversified Trust Co now owns 42,579 shares of the medical research company’s stock worth $8,087,000 after buying an additional 15,487 shares during the last quarter. Finally, Nichols & Pratt Advisers LLP MA boosted its holdings in shares of IQVIA by 8.6% during the 3rd quarter. Nichols & Pratt Advisers LLP MA now owns 122,603 shares of the medical research company’s stock worth $23,287,000 after buying an additional 9,684 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on IQV shares. JPMorgan Chase & Co. dropped their target price on shares of IQVIA from $255.00 to $225.00 and set an “overweight” rating on the stock in a report on Friday, February 6th. Jefferies Financial Group cut their price objective on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research report on Friday, February 6th. BMO Capital Markets set a $250.00 target price on IQVIA in a report on Friday, February 6th. Evercore reiterated an “outperform” rating and set a $225.00 price target on shares of IQVIA in a report on Thursday, February 5th. Finally, Citigroup reduced their price objective on IQVIA from $230.00 to $200.00 and set a “neutral” rating for the company in a research report on Friday, February 6th. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $238.20.

IQVIA Trading Down 1.5%

Shares of IQV stock opened at $164.44 on Wednesday. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.70 and a current ratio of 0.75. The firm has a fifty day moving average of $220.91 and a 200-day moving average of $208.93. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $247.04. The stock has a market cap of $28.00 billion, a price-to-earnings ratio of 20.92, a P/E/G ratio of 1.61 and a beta of 1.37.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.40 by $0.02. The firm had revenue of $4.36 billion during the quarter, compared to analyst estimates of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.12 earnings per share. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.